Engineered cytokines, AI-designed polypeptides, pharmaceutical compositions

This patent application publication discloses engineered cytokines and polypeptide structures designed using artificial intelligence methods, including artificial neural network machine learning protocols and molecular dynamics simulations. The technology covers compositions with modulated stability, potency, and developability characteristics, along with pharmaceutical formulations for treating subjects. The application is classified under CPC C07K 14/54 (interleukins).

Patent applicants and pharmaceutical companies developing cytokine-based therapeutics should review this published application to understand potential prior art and freedom-to-operate considerations. Researchers working with AI-designed polypeptides and engineered cytokines should assess whether their innovations overlap with the disclosed subject matter. While this is a publication rather than an issued patent, it establishes a priority date and begins the examination process.